Compare
Gilead Sciences vs Merck
MonkScore ranges and fundamentals, side by side
Key facts
Gilead Sciences and Merck: key facts
- In fiscal 2025, Gilead Sciences, Inc. reported revenue of $29.4B and net income of $8.5B.
- In fiscal 2025, Merck & Co., Inc. reported revenue of $64.9B and net income of $18.3B.
- Gilead Sciences, Inc.'s revenue grew 1.9% a year from fiscal 2021 to fiscal 2025.
- Merck & Co., Inc.'s revenue grew 7.5% a year from fiscal 2021 to fiscal 2025.
- Gilead Sciences, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- Merck & Co., Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Gilead Sciences, Inc. reported revenue of $31.0B and net income of -$3.9B.
- In the twelve months to 30 September 2026, Merck & Co., Inc. reported revenue of $67.3B and net income of $2.5B.
Side by side
Gilead Sciences and Merck, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Gilead Sciences, Inc.NASDAQ:GILD | Merck & Co., Inc.NYSE:MRK |
|---|---|---|
| MonkScore | ||
| MonkScore range | 90–100as of October 2026 | 60–70as of October 2026 |
| Sector rank | 39 of 628 in Healthcare | 266 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Latest fiscal year | ||
| Revenue | $29.4BFY 2025 | $64.9BFY 2025 |
| Net income | $8.5BFY 2025 | $18.3BFY 2025 |
| Free cash flow | $9.5BFY 2025 | $12.4BFY 2025 |
| Operating cash flow | $10.0BFY 2025 | $16.5BFY 2025 |
| Total debt | $24.9BFY 2025 | $50.5BFY 2025 |
| Cash | $7.6BFY 2025 | $14.6BFY 2025 |
| Last 12 months | ||
| Revenue | $31.0Bto 30 September 2026 | $67.3Bto 30 September 2026 |
| Net income | -$3.9Bto 30 September 2026 | $2.5Bto 30 September 2026 |
| Free cash flow | $14.0Bto 30 September 2026 | $16.1Bto 30 September 2026 |
| Operating cash flow | $14.5Bto 30 September 2026 | $20.0Bto 30 September 2026 |
| Total debt | $26.2Bto 30 September 2026 | $53.9Bto 30 September 2026 |
| Cash | $6.4Bto 30 September 2026 | $6.8Bto 30 September 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.